U
BIS icon

UBS’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

UBS’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-13
Closed -$9K – 10417
2014
Q1 		$9K Buy
+13
New +$8.68K ﹤0.01% 8984

Other funds holding BIS

HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BMO
Beck Mack & Oliver New York $4.85B AUM 9.66% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS's BIS Position: Q3 2014 in Review

UBS reduced its ProShares UltraShort NASDAQ Biotechnology (BIS) stake by 33% in Q3 2014, selling an estimated $9.05K and leaving 35 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #8185.

UBS first reported a position in BIS in Q2 2013 and has held it in 5 quarters since. The position peaked at $37K in Q2 2013. 16 funds tracked by Wall St. Rank hold BIS as of Q3 2014.

  • UBS held 35 shares of ProShares UltraShort NASDAQ Biotechnology worth $17K as of Q3 2014.
  • UBS sold 17 ProShares UltraShort NASDAQ Biotechnology shares in Q3 2014, an estimated $9.05K.
  • ProShares UltraShort NASDAQ Biotechnology made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8185 holding.
  • UBS first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2013 and has held it in 5 quarters since.
  • UBS's ProShares UltraShort NASDAQ Biotechnology position peaked at $37K in Q2 2013.
  • 16 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.